{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:27Z","timestamp":1793394507330,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017035","name":"Fondation ISREC","doi-asserted-by":"publisher","award":["2022.136.1"],"award-info":[{"award-number":["2022.136.1"]}],"id":[{"id":"10.13039\/501100017035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BLC) remains a clinically challenging malignancy due to its pronounced inter- and intra-patient heterogeneity, which contributes to therapeutic resistance and poor clinical outcomes. Capturing and modeling this complexity is essential for the development of effective, personalized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate molecularly and functionally BLC heterogeneity, this study employed three-dimensional patient-derived organoids (PDOs) and ex vivo tissue slice culture as advanced preclinical models. PDOs were established from a patient\u2019s cohort enrolled at Regina Elena National Cancer Institute in Rome using spatially distinct tumor samples from central (TC) and peripheral (TP) tumor regions to preserve intratumoral heterogeneity. Genomic and transcriptomic fidelity between PDOs and their parental tumors was assessed through multi-omics analyses. Functional assays were conducted to evaluate therapeutic responses. A second patient cohort from the University of Bern, was used to further characterize cellular and microenvironmental features of BLC samples combining ex vivo tissue culture and multiparametric-Flow Cytometry (FACS) to address treatment-induced cancer cell plasticity and epithelial-marker expression dynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PDOs recapitulated the genomic and transcriptomic landscapes of the original tumors. Early passage PDOs retained components of the tumor microenvironment, including immune cell subsets, suggesting their relevance for ex vivo modeling of tumor-immune interactions. Functional assays revealed spatial heterogeneous responses to both chemotherapy and EGFR\/FGFR-targeted therapies. A corresponding reduction of the EGFR-high basal-like population was observed in ex vivo tissue cultures. In contrast, treatment with a PD-1 immune checkpoint inhibitor showed consistent responses across PDOs regions but correlated with the degree of immune infiltration observed in the parental tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This integrated dual-cohort approach demonstrates that both BLC PDOs and ex vivo tissue cultures offer a versatile and faithful platform for dissecting BLC heterogeneity and advancing functional precision medicine recapitulating patient-specific immune-tumor interactions observed in native tissues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03701-x","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:46:27Z","timestamp":1775054787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening"],"prefix":"10.1186","volume":"45","author":[{"given":"Carlotta","family":"Frascolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Macedo-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"De Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Angela","family":"Covino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Minoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Radic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pulito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Vaccarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Runci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Vinik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Lev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Strano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindusa Ana Maria","family":"Arteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Donzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Kruithof-de Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"7","key":"3701_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","volume":"21","author":"CC Guo","year":"2024","unstructured":"Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol. 2024;21(7):391\u2013405. https:\/\/doi.org\/10.1038\/s41585-023-00847-7.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"3701_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primer. 2023;9(1):58. https:\/\/doi.org\/10.1038\/s41572-023-00468-9. PubMed PMID: 37884563; PubMed Central PMCID: PMC11218610.","journal-title":"Bladder cancer Nat Rev Dis Primer"},{"issue":"384","key":"3701_CR3","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"12","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743. https:\/\/doi.org\/10.1136\/bmj-2023-076743.\u00a0PubMed PMID: 38346808.","journal-title":"BMJ"},{"issue":"5","key":"3701_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259\u201370. https:\/\/doi.org\/10.1038\/s41585-020-0304-1. PubMed PMID: 32235944; PubMed Central PMCID: PMC7968350.","journal-title":"Nat Rev Urol"},{"issue":"19","key":"3701_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine\u2013Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"3701_CR6","doi-asserted-by":"publisher","unstructured":"Radi\u0107 M, Egger M, Kruithof-de Julio M, Seiler R. Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges. Eur Urol Focus. 2024. https:\/\/doi.org\/10.1016\/j.euf.2024.08.008.","DOI":"10.1016\/j.euf.2024.08.008"},{"issue":"14","key":"3701_CR7","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","volume":"18","author":"M Minoli","year":"2023","unstructured":"Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat Commun. 2023;14:2214. https:\/\/doi.org\/10.1038\/s41467-023-37696-2. PubMed PMID: 37072390; PubMed Central PMCID: PMC10113240.","journal-title":"Nat Commun"},{"key":"3701_CR8","unstructured":"sarek: Introduction. Available from: https:\/\/nf-co.re\/sarek\/3.5.1.html.\u00a0Cited 2025 Oct 9."},{"key":"3701_CR9","doi-asserted-by":"publisher","unstructured":"Antonello A, Bergamin R, Calonaci N, Househam J, Milite S, Williams MJ, et al. Computational validation of clonal and subclonal copy number alterations from bulk tumour sequencing. bioRxiv; 2023. p. 2021.02.13.429885. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.02.13.429885v4. https:\/\/doi.org\/10.1101\/2021.02.13.429885. Cited 2025 Oct 9.","DOI":"10.1101\/2021.02.13.429885"},{"key":"3701_CR10","unstructured":"rnaseq: Introduction. Available from: https:\/\/nf-co.re\/rnaseq\/3.19.0.html. Cited 2025 Oct 9."},{"key":"3701_CR11","doi-asserted-by":"publisher","unstructured":"Patel H, Ewels P, Peltzer A, Hammar\u00e9n R, Botvinnik O, Sturm G, et al. nf-core\/rnaseq: nf-core\/rnaseq v3.4 - Aluminium Aardvark. Zenodo; 2021. Available from: https:\/\/doi.org\/10.5281\/zenodo.5550247. Cited 2025 Oct 9.","DOI":"10.5281\/zenodo.5550247"},{"issue":"6","key":"3701_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1073\/pnas.1120605109","volume":"109","author":"JP Volkmer","year":"2012","unstructured":"Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012;109(6):2078\u201383. https:\/\/doi.org\/10.1073\/pnas.1120605109. PubMed PMID: 22308455; PubMed Central PMCID: PMC3277552.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3701_CR13","doi-asserted-by":"publisher","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017;72(4):544\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.030. PubMed PMID: 28390739.","DOI":"10.1016\/j.eururo.2017.03.030"},{"issue":"3","key":"3701_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/path.5083","volume":"245","author":"S Karkampouna","year":"2018","unstructured":"Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, et al. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. J Pathol. 2018;245(3):297\u2013310. https:\/\/doi.org\/10.1002\/path.5083. PubMed PMID: 29604056.","journal-title":"J Pathol"},{"key":"3701_CR15","doi-asserted-by":"publisher","unstructured":"van de Merbel AF, van der Horst G, van der Pluijm G. Patient-derived tumour models for personalized therapeutics in urological cancers. Nat Rev Urol. 2021;18(1):33\u201345. https:\/\/doi.org\/10.1038\/s41585-020-00389-2.","DOI":"10.1038\/s41585-020-00389-2"},{"issue":"3","key":"3701_CR16","doi-asserted-by":"publisher","first-page":"e010572","DOI":"10.1136\/jitc-2024-010572","volume":"13","author":"GM Galarza Fortuna","year":"2025","unstructured":"Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, et al. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025;13(3):e010572. https:\/\/doi.org\/10.1136\/jitc-2024-010572. PubMed PMID: 40102029; PubMed Central PMCID: PMC11927433.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"3701_CR17","doi-asserted-by":"publisher","first-page":"e2308438","DOI":"10.1002\/advs.202308438","volume":"11","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Jin W, Qian K, Ju L, Wang G, Wu K, et al. Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation from an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma. Adv Sci. 2024;11(24):e2308438. https:\/\/doi.org\/10.1002\/advs.202308438. PubMed PMID: 38582099; PubMed Central PMCID: PMC11200000.","journal-title":"Adv Sci"},{"issue":"1","key":"3701_CR18","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1038\/s41467-019-12307-1","volume":"10","author":"CP Santos","year":"2019","unstructured":"Santos CP, Lapi E, Mart\u00ednez de Villarreal J, \u00c1lvaro-Espinosa L, Fern\u00e1ndez-Barral A, Barb\u00e1chano A, et al. Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity. Nat Commun. 2019;10(1):4407. https:\/\/doi.org\/10.1038\/s41467-019-12307-1.\u00a0PubMed PMID: 31562298; PubMed Central PMCID: PMC6764959.","journal-title":"Nat Commun"},{"issue":"8","key":"3701_CR19","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers15133466","volume":"15","author":"R Khademi","year":"2023","unstructured":"Khademi R, Malekzadeh H, Bahrami S, Saki N, Khademi R, Villa-Diaz LG. Regulation and Functions of \u03b16-Integrin (CD49f) in Cancer Biology. Cancers. 2023;15(13):3466. https:\/\/doi.org\/10.3390\/cancers15133466. PubMed PMID: 37444576; PubMed Central PMCID: PMC10341356.","journal-title":"Cancers"},{"issue":"1","key":"3701_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13402-021-00657-2","volume":"45","author":"C Martins-Lima","year":"2022","unstructured":"Martins-Lima C, Miranda-Gon\u00e7alves V, Lobo J, Const\u00e2ncio V, Leite-Silva P, Guimar\u00e3es-Teixeira C, et al. Cadherin switches during epithelial-mesenchymal transition: CDH4\/RCAD downregulation reduces bladder cancer progression. Cell Oncol. 2022;45(1):135\u201349. https:\/\/doi.org\/10.1007\/s13402-021-00657-2. PubMed PMID: 35064910.","journal-title":"Cell Oncol"},{"issue":"7","key":"3701_CR21","doi-asserted-by":"publisher","first-page":"XC01","DOI":"10.7860\/JCDR\/2016\/18181.8126","volume":"10","author":"P Rajkumar","year":"2016","unstructured":"Rajkumar P, Mathew BS, Das S, Isaiah R, John S, Prabha R, et al. Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery. J Clin Diagn Res JCDR. 2016;10(7):XC01\u20134. https:\/\/doi.org\/10.7860\/JCDR\/2016\/18181.8126. PubMed PMID: 27630935; PubMed Central PMCID: PMC5020194.","journal-title":"J Clin Diagn Res JCDR"},{"key":"3701_CR22","doi-asserted-by":"publisher","unstructured":"Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2002;13(9):1479\u201389. https:\/\/doi.org\/10.1093\/annonc\/mdf219. PubMed PMID: 12196375.","DOI":"10.1093\/annonc\/mdf219"},{"key":"3701_CR23","unstructured":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types - ScienceDirect. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0923753419360703?via%3Dihub. Cited 2025 Jun 4."},{"key":"3701_CR24","doi-asserted-by":"publisher","unstructured":"Lee K, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, et al. Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. The Oncologist. 2018 Feb;23(2):155\u2013e17. https:\/\/doi.org\/10.1634\/theoncologist.2017-0528. PubMed PMID: 29158363; PubMed Central PMCID: PMC5813749.","DOI":"10.1634\/theoncologist.2017-0528"},{"key":"3701_CR25","doi-asserted-by":"publisher","unstructured":"Medle B, Sj\u00f6dahl G, Eriksson P, Liedberg F, H\u00f6glund M, Bernardo C. Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review. Cancers. 2022;14(9):2062. https:\/\/doi.org\/10.3390\/cancers14092062. PubMed PMID: 35565191; PubMed Central PMCID: PMC9104249.","DOI":"10.3390\/cancers14092062"},{"key":"3701_CR26","doi-asserted-by":"publisher","unstructured":"Noeraparast M, Krajina K, Pichler R, Nieders\u00fc\u00df\u2010Beke D, Shariat SF, Gr\u00fcnwald V, et al. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer Commun. 2024;44(10):1189\u2013208. https:\/\/doi.org\/10.1002\/cac2.12602. PubMed PMID: 39161208; PubMed Central PMCID: PMC11483561.","DOI":"10.1002\/cac2.12602"},{"key":"3701_CR27","doi-asserted-by":"publisher","unstructured":"Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24(8):925\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9. PubMed PMID: 37541273; PubMed Central PMCID: PMC11224843.","DOI":"10.1016\/S1470-2045(23)00275-9"},{"key":"3701_CR28","doi-asserted-by":"publisher","unstructured":"Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21(4):312\u201329. https:\/\/doi.org\/10.1038\/s41571-024-00869-z.","DOI":"10.1038\/s41571-024-00869-z"},{"key":"3701_CR29","doi-asserted-by":"publisher","unstructured":"Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, et al. Phase 2 Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K1. JCO Precis Oncol. 2024;8:e2300406. https:\/\/doi.org\/10.1200\/PO.23.00406. PubMed PMID: 38603651; PubMed Central PMCID: PMC11623914.","DOI":"10.1200\/PO.23.00406"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03701-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03701-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:20:37Z","timestamp":1781644837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03701-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3701"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03701-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Generation of patient-derived organoids and multiparametric analyses on BLC tissues was approved by Ethic Committee of Rome (approval no. IFO 1767\/22) and from Ethic Committee of Bern (Cantonal Ethical approval KEK 06\/03 and 2017\u201302295). All patients signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"117"}}